knowledge -WSS

knowledge

author：explore 2025-09-06 03:53:36 - browse：4

Adobe

The Food and Drug Administration is expected to approve Merck’s drug to treat a rare lung disorder called pulmonary arterial hypertension on Tuesday, making available a novel treatment for a deadly condition that’s long been challenging to treat.

In a large trial published last year, the drug, called sotatercept, exceeded expectations in significantly increasing the distance that patients could walk and cutting the risk that their condition would worsen, that they would die, and that they would need new treatments.

Pulmonary arterial hypertension, or PAH, is estimated to occur in 15 to 50 per million people, mostly in women. It’s characterized by a proliferation of cells in the blood vessels that connect the right side of heart to the lungs, making it harder for blood to pass through and leading the heart to have to work harder to pump blood into the lungs. The disease, which causes difficulty breathing, fatigue and dizziness, has a high mortality rate, with one study finding that one-fifth of patients died at around three years after diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

WSS

Vertigo drug brings hope for rare neuron disorder, Niemann

Microsoft's Peter Lee: Generative AI could help doctors be more human

Families look for replacement for GSK asthma drug Flovent

Readout Newsletter: BridgeBio, Akero, and human embryo models

A $475,000 price tag for a new cancer drug: crazy or meh?

Novo Nordisk to expand supply of Wegovy for U.S. patients

focus

knowledge

entertainment

Cancer drug shortages should be causing more outrage

A new approach to psychiatric drug development

In Memoriam: Notable people who died in 2023

Lack of health data on LGBTQ+ people has serious consequences

The cancer drug shortage isn’t new — and neither are the solutions

Stem cell biologist probes earliest stages of human development

Hollywood unions extend contract negotiations for actors

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

State Dept. review finds Biden bears some blame for Afghanistan failures

Microsoft's Peter Lee: Generative AI could help doctors be more human

knowledge

Novo Nordisk to expand supply of Wegovy for U.S. patients

Readout Newsletter: BridgeBio, Akero, and human embryo models

Vertigo drug brings hope for rare neuron disorder, Niemann

Medicare drug price negotiation’s day in court

Why Talkspace is targeting Medicare, a tricky market

The public health thinking behind the CDC’s new Covid guidance

leisure time

hotspot

knowledge

focus